These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7025545)
81. Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Sonino N; Chow D; Levine LS; New MI Clin Endocrinol (Oxf); 1981 Jan; 14(1):31-9. PubMed ID: 7226574 [TBL] [Abstract][Full Text] [Related]
87. Dexamethasone-suppressible hyperaldosteronism: studies on overproduction of 18-hydroxycortisol in three affected family members. Davis JR; Burt D; Corrie JE; Edwards CR; Sheppard MC Clin Endocrinol (Oxf); 1988 Sep; 29(3):297-308. PubMed ID: 3251669 [TBL] [Abstract][Full Text] [Related]
88. Evidence for an unidentified, adrenocorticotrophic hormone-dependent mineralocorticoid maintaining hypertension in young women with hypoaldosteronism. Hoefnagels WH; Drayer JI; Hofman JA; Smals AG; Benraad TJ; Kloppenborg PW Clin Sci Mol Med Suppl; 1978 Dec; 4():271s-274s. PubMed ID: 282066 [TBL] [Abstract][Full Text] [Related]
89. Radioimmunoassay of serum deoxycorticosterone: normal values and changes of serum deoxycorticosterone after adrenal stimulation. Schöneshöfer M; Oelkers W; Harendt H Z Klin Chem Klin Biochem; 1975 Apr; 13(4):143-7. PubMed ID: 168695 [TBL] [Abstract][Full Text] [Related]
90. Effects of various adrenal inhibitors in low-renin essential hypertension. Liddle GW; Hollifield JW; Slaton PE; Wilson HM J Steroid Biochem; 1976; 7(11-12):937-40. PubMed ID: 799736 [No Abstract] [Full Text] [Related]
91. Aldosterone and Treatment-Resistant Hypertension. Leopold JA; Ingelfinger JR N Engl J Med; 2023 Feb; 388(5):464-467. PubMed ID: 36724334 [No Abstract] [Full Text] [Related]
93. Glucocorticoid-suppressible hyperaldosteronism: a paradigm of arrested adrenal zonation? Ganguly A Clin Sci (Lond); 1991 Jan; 80(1):1-7. PubMed ID: 1846785 [No Abstract] [Full Text] [Related]
94. The role of 11-deoxycorticosterone in human hypertension. Tan SY; Noth RH; Mulrow PJ Clin Sci Mol Med Suppl; 1976 Dec; 3():311s-314s. PubMed ID: 1071634 [TBL] [Abstract][Full Text] [Related]
95. Aldosterone and in vivo mineralocorticoid activity in normotensive and hypertensive man. Skrabal F J R Soc Med; 1979 Apr; 72(4):252-9. PubMed ID: 233248 [No Abstract] [Full Text] [Related]
96. Genetic screening of hypertensive patients with aldosterone hypersecretion under conditions of stress. Mourtzi N; Sertedaki A; Markou A; Piaditis GP; Katsanis N; Traeger-Synodinos J; Tsigos C; Charmandari E Hormones (Athens); 2022 Dec; 21(4):525-536. PubMed ID: 36044182 [TBL] [Abstract][Full Text] [Related]
97. Primary hyperaldosteronism. Levi M Am J Med Sci; 1990 Sep; 300(3):189-202. PubMed ID: 2240013 [No Abstract] [Full Text] [Related]
98. 19-Noraldosterone, a new mineralocorticoid. Takeda Y; Miyamori I Endocr J; 1994 Oct; 41(5):483-9. PubMed ID: 7889107 [No Abstract] [Full Text] [Related]
99. Recent advances in human steroid metabolism. Hellman L; Bradlow HL; Zumoff B Adv Clin Chem; 1970; 13():1-35. PubMed ID: 4319641 [No Abstract] [Full Text] [Related]
100. Control of hyperaldosteronism by ketoconazole. Benito P; Corpas MS; Quesada JM; Jiménez JA Drug Intell Clin Pharm; 1987 Sep; 21(9):752. PubMed ID: 3652938 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]